Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer
September 28, 2021 08:30 ET
|
Sera Prognostics
Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 ...
Sera Prognostics to be Added to Russell 2000 Index
September 20, 2021 08:30 ET
|
Sera Prognostics
SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer
September 15, 2021 08:00 ET
|
Sera Prognostics
SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health
September 14, 2021 08:00 ET
|
Sera Prognostics
Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs Positive impact on preterm births,...
Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
September 13, 2021 08:00 ET
|
Sera Prognostics
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
Sera Prognostics Reports Second Quarter 2021 Financial Results
August 30, 2021 16:05 ET
|
Sera Prognostics
SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility
August 17, 2021 08:00 ET
|
Sera Prognostics
Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare NICU and total hospital length-of-stay in preemies reduced by more than 70% Faster...
Sera Prognostics Announces Pricing of Initial Public Offering
July 14, 2021 21:03 ET
|
Sera Prognostics
SALT LAKE CITY, July 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy...
Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth
May 19, 2021 08:30 ET
|
Sera Prognostics
- The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., The Pregnancy Company®...
Evaluation of Health and Economic Benefit of the PreTRM® Test-And-Treat Strategy to Improve Maternal and Infant Health Among Commercially Insured in the US
May 18, 2021 16:13 ET
|
Sera Prognostics
– Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings SALT LAKE CITY, May 18, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy...